Roche shells out $600M for BioVeris
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Roche |
BioVeris |
$600M acquisition |
Roche Diagnostics will be able to leverage BioVeris' technology by expanding its immunochemistry business from the human diagnostics field into new market segments. |
|
Agilent Technologies |
Stratagene |
$246.2M buyout |
Agilent Technologies struck a deal to buy Stratagene, a maker of research and development tools for life science companies. |
|
Roche |
454 Life Sciences |
$155M buyout |
CuraGen--which owns 454 Life Sciences--agreed to the sale in order to gain some liquidity as it pushed several experimental cancer therapies to market. |
|
Pfizer |
pSivida |
$155M licensing pact |
The two companies will work together on a program to develop ophthalmic products. |
|
Astellas Pharma |
Regeneron |
$120M deal |
Astellas Pharma has agreed to pay Regeneron $20 million up front and up to $100 million more in order to use its VelocImmune technology to develop antibodies. |
|
Roche |
Therapeutic Human Polyclonals |
$56.5 buyout |
THP has developed a transgenic mammalian approach to creating human antibodies that Roche will now incorporate into its research center in Penzberg, Germany. |
|
AmerisourceBergen |
Xcenda |
$25M acquisition |
Xcenda will provide additional capabilities in the key areas of pharmaceutical brand services, applied health outcomes and biopharma strategies. |
|
Inhibitex |
FermaVir Pharmaceuticals |
$19M buyout |
The deal gives Inhibitex control of an experimental therapy for shingles that is about to start clinical trials. |
|
Roche |
Transgene |
$17.4M collaboration |
The collaboration pact covers covering TG 4001, a vaccine candidate for pre-cancerous cervical abnormalities. |